Dendreon

In a Reviews in Urology Author Perspectives discussion, Neal Shore, MD, moderates a conversation with Ben Lowentritt, MD, FACS, and Paul Monk, MD, exploring long-term real-world evidence with sipuleucel-T. The discussion highlights how real-world evidence informs clinical decision-making and shapes treatment strategies in mCRPC. Watch the full discussion for expert perspectives across urology and medical oncology on how this real-world evidence is influencing care. 🔗 https://brnw.ch/21x4TLu #mCRPC #Urology #Immunotherapy

The work we do doesn't just advance science, it changes lives. At Dendreon, we put patients first in everything we do, from the research we pursue to the partnerships we build. If you're passionate about shaping the future of cell therapy, we'd love to have you on the team. Explore open positions: https://brnw.ch/21x4St2 #Dendreon #CareerOpportunities #JoinOurTeam

In advanced prostate cancer, understanding disease progression depends on consistent, timely insight. Dr. Benjamin H. Lowentritt highlights how regular screening plays a critical role in helping clinicians identify changes early and better assess how the disease is evolving over time. Watch now: https://brnw.ch/21x4Q6W #ProstateCancer #mCRPC #Immunotherapy

Age is an important factor in prostate cancer. 6 in 10 diagnoses occur in men aged 65 or older, making age one of the primary risk factors for the disease. Understanding the data helps inform conversations about screening and early detection. Learn more about prostate cancer statistic: https://brnw.ch/21x1EWR #ProstateCancer #MensHealth

Every patient with metastatic castration-resistant prostate cancer (mCRPC) presents unique clinical considerations, and the treatment landscape continues to evolve. As the field continues to advance, which topic would you like to learn more about? Vote in the poll below and join the conversation in the comments. #mCRPC #Urology #Oncology

Every day, we put excellence into action. With a proven clinical and regulatory foundation, we can help life-saving therapies move seamlessly from trials to patients, delivering hope where it matters most. Learn more about our work: https://brnw.ch/21x0GaP #Innovation #Dendreon

Putting patients first is at the heart of what we do. If you're passionate about helping others and looking for a unique career opportunity, join our driven team! 🔗 View all current job listings: https://brnw.ch/21x4sFQ #Dendreon #JoinOurTeam

🔴 Live from the Urology Management Alliance Summit 2026 in Arlington: Dr. Mike Bivins, President of Urology Centers of Alabama, presented on personalized approaches to therapeutic layering with immunotherapy in urologic care. As the treatment landscape for advanced prostate cancer continues to evolve, many clinicians are exploring how treatment sequencing and personalization may factor into care planning. Dr. Bivins' presentation offered his perspective on these considerations for practicing urologists. We're proud to support ongoing dialogue among healthcare professionals in the urology community. #UMASummit2026 #UrologyLeadership #PersonalizedCare

Every personalized cell-based therapy begins with a critical first step: apheresis. "The Use of Apheresis in Personalized Cell-Mediated Treatment of Prostate Cancer" examines how this process enables the collection of a patient's own immune cells, laying the foundation for individualized treatment approaches in prostate cancer. Read more: https://brnw.ch/21x4beC #ProstateCancer #Immunotherapy #Apheresis #Dendreon

How does #Immunotherapy fight cancer? Learn how this treatment approach can activate the immune system to help in the fight against prostate cancer. ▶️ https://brnw.ch/21x49qQ #Oncology #Dendreon